Role of topiramate versus propranolol in preventive treatment of chronic migraine
Phase 3
- Conditions
- Health Condition 1: G437- Chronic migraine without auraHealth Condition 2: G438- Other migraine
- Registration Number
- CTRI/2019/05/018997
- Lead Sponsor
- I
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Closed to Recruitment of Participants
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patients aged 18-65 years, either male or female who fulfills the diagnostic criteria laid down by ICHD 3 for Chronic migraine and not on any prophylactic treatment.
Exclusion Criteria
All patients with a clinical phenotype of CM but on further investigation, found to have a
secondary cause for their headaches will be excluded. Pregnant women, patient with known
allergies against propranolol and/or topiramate, patients with history of bronchial asthma,
Chronic obstructive pulmonary disease (COPD), diabetes, bradycardia or heart blocks,
congestive heart failure (CHF), glaucoma, renal stones, dementia, psychosis and severe
depression shall be excluded from the study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Primary endpoints <br/ ><br>1. Change in migraine days per 28 days (Migraine day is defined as a calendar day <br/ ><br>when the patient reported â?¥4 continuous hours of headache meeting ICHD 3 criteria <br/ ><br>for migraine)Timepoint: It will be assessed at the baseline and then after 20 weeks of drug administration i.e at week 24 of trial.
- Secondary Outcome Measures
Name Time Method